OvaSure Guidance, June 4, 2009

The Society of Gynecologic Oncologists has issued a position statement on a new ovarian cancer screening test called OvaSure™. The Foundation for Women’s Cancer is sharing this statement with you as a Guidance to Women.

We all share the goal of early detection of ovarian cancer, but the OvaSure™ test has not undergone the rigorous clinical trials testing needed to demonstrate its safety and efficacy. For a screening test such as this to be considered effective, a clinical trial must demonstrate a reduction in deaths from ovarian cancer in a population of women evaluated with the test.

You might ask what is the harm in endorsing any test that might help reduce deaths from ovarian cancer? The potential harm comes from several possible problems including: 1) false reassurance from a negative test; 2) the possibility of unnecessary surgeries; and 3) the significant stress and anxiety that may come from a false positive test.

We all look forward to the day when a proven screening test is available, unfortunately we aren’t there yet. Please distribute this attached SGO statement as you feel appropriate.

Spotlight

SGO, ASCCP Clarify Recommendations of Primary HPV Testing for Cervical Cancer Screening. Read the release.

Awareness

We’re pleased to partner with the Dana Farber Cancer Institute to promote their recent webchat on cervical cancer treatment - watch now!

Research

The Foundation’s research award winners will be notified in January. Thank you to all who sent in their applications.

Education

The next Gynecologic Cancer Survivors Course is February 7-8 in Anchorage, Alaska. For more information, click here.